XM does not provide services to residents of the United States of America.

Aurinia Pharmaceuticals jumps after Tang Capital reports 5.1% stake in co



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-Aurinia Pharmaceuticals jumps after Tang Capital reports 5.1% stake in co</title></head><body>

** U.S.-listed shares of drugmaker Aurinia Pharmaceuticals AUPH.O up 6.6% at $7.01

** Tang Capital Management reports 5.1% stake in AUPH as of Sept. 6

** Separately, AUPH said on Thursday it has restructured its board and has allowed CEO Peter Greenleaf to continue as a director

** AUPH says Greenleaf had conditionally resigned as a director because he received less-than-majority support at the 2024 AGM

** Company's board says it has considered all relevant factors and determined there are exceptional circumstances that warrant the rejection of Greenleaf's conditional resignation

** AUPH says its board has appointed Kevin Tang, president of Tang Capital Management as a director

** Shareholder Lucien Selce, co-founder of Vista Capital Management, has been urging other investors in AUPH to remove the CEO

** Stock was down nearly 27% YTD



Reporting by Ananya Mariam Rajesh in Bengaluru

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.